1Bourdon J C,Laurenzi VD,Melino G,et al.p53:25 years of research and more questions to answer[J].Cell Death and Differentiation,2003,10:397 ～ 399.
2Peng Z.Current status of gendicine in China:recombinant human Ad-p53 agent for treatment of cancers[J].Hum Gene Ther.2005,16(9):1016 ～ 1027.
3Nemunaitis BJ,Swisher SG,Timmons T,et al.Adenovirus -mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer[J].J Clin Oncol,2000,18(3):609 ～622.
4David Lane.Curing cancer with p53[J].N Engl J Med,2004,350(26):2711 ～ 2712.
5Lorne JH,Perwez H,Curtis CH.p53:25 years after its discovery[J].Trends in Pharmacol Sci,2004,25 (4):177 ～181.
6Judith K Wolf,Gordon BM,Lisa B,et al.Adenovirus-mediated p53 growth inhibition of ovarian cancer cells Is Independent of endogenous p53 status[J].Gynecol Oncol,1999,75 (4):261 ～266.
7Balint E,KH Vousden.Activation and activities of the p53 tumour suppressor protein[J].Bri J Cancer,2001,85 (12):1813 ～1823.
8Louis AZ,Donna C,James M,et al.Safety of adenoviral vectors:results of clinical investigations in 445 cancer patients treated with advexin? (Adenoviral p53) gene therapy[J].Molecular therapy,2004,9(S1):385 ～ 386.
9Alain GZ,Christian M.Why did p53 gene therapy fail in ovarian cancer[J] ? L Oncol,2003,4(7):415 ～422.
